MX2020007882A - Variantes fc con unión mejorada a fcrn y semivida prolongada. - Google Patents
Variantes fc con unión mejorada a fcrn y semivida prolongada.Info
- Publication number
- MX2020007882A MX2020007882A MX2020007882A MX2020007882A MX2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A MX 2020007882 A MX2020007882 A MX 2020007882A
- Authority
- MX
- Mexico
- Prior art keywords
- binding polypeptides
- fcrn
- variants
- life
- longer half
- Prior art date
Links
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción proporciona polipéptidos de unión (p. ej., anticuerpos e inmunoadhesinas) que comprenden un dominio de Fc modificado. La presente descripción también proporciona ácidos nucleicos que codifican los polipéptidos de unión, vectores de expresión recombinantes, y células huésped para preparar tales polipéptidos de unión. También se proporcionan métodos de uso de los polipéptidos de unión descritos en este documento para tratar la enfermedad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007882A true MX2020007882A (es) | 2020-12-03 |
Family
ID=65520379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007882A MX2020007882A (es) | 2018-01-26 | 2019-01-25 | Variantes fc con unión mejorada a fcrn y semivida prolongada. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (es) |
| EP (1) | EP3743441A1 (es) |
| JP (2) | JP7399880B2 (es) |
| KR (2) | KR102748986B1 (es) |
| CN (2) | CN119350481A (es) |
| AU (2) | AU2019212638B2 (es) |
| BR (1) | BR112020015006A2 (es) |
| CA (1) | CA3089602A1 (es) |
| CO (1) | CO2020010269A2 (es) |
| IL (2) | IL276286B2 (es) |
| MX (1) | MX2020007882A (es) |
| MY (1) | MY203898A (es) |
| NZ (1) | NZ767453A (es) |
| PH (1) | PH12020551134A1 (es) |
| SG (1) | SG11202006905YA (es) |
| TW (1) | TW201940512A (es) |
| WO (1) | WO2019147973A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119350481A (zh) * | 2018-01-26 | 2025-01-24 | 建新公司 | 具有与FcRn增强的结合及延长的半衰期的Fc变体 |
| TW202120539A (zh) * | 2019-07-25 | 2021-06-01 | 美商健臻公司 | 以FcRn拮抗劑治療抗體媒介之病症的方法 |
| JP2023526225A (ja) * | 2020-05-11 | 2023-06-21 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
| CA3193930A1 (en) * | 2020-10-29 | 2022-05-05 | Formycon Ag | Ace2 fusion proteins and uses thereof |
| WO2022249146A1 (en) | 2021-05-27 | 2022-12-01 | Sanofi | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY |
| CA3227716A1 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| WO2023064856A1 (en) * | 2021-10-13 | 2023-04-20 | The Wistar Institute Of Anatomy And Biology | In vivo interacting protein domains and methods of use thereof |
| TW202413419A (zh) | 2022-05-27 | 2024-04-01 | 法商賽諾菲公司 | 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物 |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| AR130869A1 (es) | 2022-10-25 | 2025-01-29 | Ablynx Nv | Polipéptidos de variantes de fc diseñados por glicoingeniería con función efectora aumentada |
| AR131281A1 (es) | 2022-12-05 | 2025-03-05 | Sanofi Sa | Proteínas de unión al receptor de transferrina |
| WO2025088546A1 (en) | 2023-10-25 | 2025-05-01 | Ablynx N.V. | Fc domain variants with enhanced fc receptor binding |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69232604T2 (de) | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | Antikörperkonstrukte |
| AU6873396A (en) | 1995-10-16 | 1997-05-07 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| HU230769B1 (hu) * | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| BRPI0515230A (pt) * | 2004-08-19 | 2008-07-15 | Genentech Inc | polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2314618A3 (en) | 2004-11-12 | 2011-10-19 | Xencor Inc. | Fc variants with altered binding to FcRn |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2373689A1 (en) * | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| CA2785178C (en) * | 2009-12-23 | 2019-09-03 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| EP3939996A1 (en) * | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| CA2904805A1 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| MX378451B (es) * | 2014-11-06 | 2025-03-11 | Hoffmann La Roche | Variantes de regiòn fc con uniòn del receptor fc neonatal (fcrn) modificado y mètodos de uso. |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| BR112019001989A2 (pt) * | 2016-08-02 | 2019-08-20 | Visterra Inc | polipeptídeos projetados e usos dos mesmos |
| CN119350481A (zh) * | 2018-01-26 | 2025-01-24 | 建新公司 | 具有与FcRn增强的结合及延长的半衰期的Fc变体 |
-
2019
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
- 2019-01-25 CN CN201980015900.4A patent/CN111788221A/zh active Pending
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en active Application Filing
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 NZ NZ767453A patent/NZ767453A/en unknown
-
2020
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021511830A (ja) | 2021-05-13 |
| AU2025204826A1 (en) | 2025-07-17 |
| IL276286A (en) | 2020-09-30 |
| AU2019212638A1 (en) | 2020-09-17 |
| PH12020551134A1 (en) | 2021-05-31 |
| TW201940512A (zh) | 2019-10-16 |
| CA3089602A1 (en) | 2019-08-01 |
| IL276286B2 (en) | 2025-07-01 |
| CN119350481A (zh) | 2025-01-24 |
| MY203898A (en) | 2024-07-23 |
| CO2020010269A2 (es) | 2020-12-10 |
| BR112020015006A2 (pt) | 2020-12-29 |
| SG11202006905YA (en) | 2020-08-28 |
| KR102748986B1 (ko) | 2025-01-02 |
| RU2020128177A (ru) | 2022-02-28 |
| IL276286B1 (en) | 2025-03-01 |
| KR20200115568A (ko) | 2020-10-07 |
| JP7399880B2 (ja) | 2023-12-18 |
| AU2019212638B2 (en) | 2025-04-03 |
| NZ767453A (en) | 2025-03-28 |
| JP2024026255A (ja) | 2024-02-28 |
| US20190263934A1 (en) | 2019-08-29 |
| KR20250008975A (ko) | 2025-01-16 |
| EP3743441A1 (en) | 2020-12-02 |
| CN111788221A (zh) | 2020-10-16 |
| IL318916A (en) | 2025-04-01 |
| WO2019147973A1 (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007882A (es) | Variantes fc con unión mejorada a fcrn y semivida prolongada. | |
| EA201691304A1 (ru) | АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA202092093A1 (ru) | Композиции и способы перепрограммирования tcr с применением слитых белков | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| MX2021010354A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| AU2019343184A8 (en) | Compositions and methods for treating cancer with anti-CD123 immunotherapy | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| MX2023007211A (es) | Anticuerpos antimiostatina y metodos de uso. | |
| EA202091198A1 (ru) | Полипептиды, содержащие домен d, и их применение | |
| PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
| PH12018502361B1 (en) | Gdf15 fusion proteins and uses thereof | |
| MX2022001049A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos. | |
| SG10201808158UA (en) | Site-specific glycoengineering of targeting moieties | |
| MX386491B (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| MX388739B (es) | Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso. | |
| EA201690299A1 (ru) | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ | |
| EP4219702A3 (en) | Enzyme variants and polynucleotides encoding the same | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| MX381726B (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| EA202091239A1 (ru) | Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение | |
| PH12021551633A1 (en) | Prostate neoantigens and their uses | |
| EA201990822A1 (ru) | Иммуномодулирующие слитые белки | |
| MX2022007840A (es) | Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla4) y uso del mismo. | |
| EA201792274A1 (ru) | Слитые молекулы вариант iii рецептора эпидермального фактора роста-мезотелин и способы их применения |